IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION. TASK ORDER 03 OBLIGATED IN THE AMOUNT OF $136
Abstract
The Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA)
supports research and development of new medications for the treatment of drug addiction. Medication development
involves in vitro evaluations, nonclinical pharmacology and toxicology studies, pharmaceutical development, and
clinical evaluation of new medications for treating addiction.
Key facts
- NIH application ID
- 10710585
- Project number
- 75N95021D00025-P00002-9999-2
- Recipient
- SRI INTERNATIONAL
- Principal Investigator
- MARY BASTIDA
- Activity code
- N01
- Funding institute
- NIH
- Fiscal year
- 2022
- Award amount
- $165,694
- Award type
- —
- Project period
- 2021-09-27 → 2026-09-26